Wall Street brokerages expect Compugen Ltd. (NASDAQ:CGEN) to post earnings of ($0.19) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Compugen’s earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.18). Compugen also reported earnings per share of ($0.19) in the same quarter last year. The business is scheduled to report its next quarterly earnings results on Tuesday, November 6th.

On average, analysts expect that Compugen will report full year earnings of ($0.45) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.43). For the next fiscal year, analysts expect that the company will post earnings of ($0.81) per share, with EPS estimates ranging from ($0.89) to ($0.73). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Compugen.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.19).

CGEN has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Compugen from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. ValuEngine raised Compugen from a “sell” rating to a “hold” rating in a report on Friday, June 1st.

Shares of CGEN traded down $0.05 during trading hours on Monday, reaching $3.90. 53,400 shares of the company’s stock traded hands, compared to its average volume of 233,257. The company has a market cap of $202.61 million, a PE ratio of -5.42 and a beta of 1.12. Compugen has a 12 month low of $2.25 and a 12 month high of $5.00.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. ARK Investment Management LLC raised its holdings in shares of Compugen by 34.5% during the 2nd quarter. ARK Investment Management LLC now owns 5,372,874 shares of the biotechnology company’s stock valued at $17,730,000 after buying an additional 1,379,123 shares in the last quarter. Taylor Frigon Capital Management LLC raised its holdings in shares of Compugen by 24.3% during the 2nd quarter. Taylor Frigon Capital Management LLC now owns 666,302 shares of the biotechnology company’s stock valued at $2,199,000 after buying an additional 130,217 shares in the last quarter. Commonwealth Equity Services LLC purchased a new position in shares of Compugen during the 2nd quarter valued at about $106,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Compugen by 34.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 167,600 shares of the biotechnology company’s stock valued at $553,000 after buying an additional 42,900 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Compugen by 35.5% during the 1st quarter. Jane Street Group LLC now owns 103,823 shares of the biotechnology company’s stock valued at $462,000 after buying an additional 27,214 shares in the last quarter. 20.77% of the stock is currently owned by institutional investors.

About Compugen

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Get a free copy of the Zacks research report on Compugen (CGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.